WARRANT TO PURCHASE COMMON STOCK RespireRx Pharmaceuticals Inc.Warrant Agreement • October 14th, 2020 • RespireRx Pharmaceuticals Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 14th, 2020 Company Industry JurisdictionTHIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, EMA Financial LLC or its permitted assigns (the “Holder”) is entitled, upon the terms and conditions hereof, and subject to the limitations on exercise hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. New York time on September 30, 2023 (the “Termination Date”) but not thereafter, to subscribe for and purchase from RespireRx Pharmaceuticals Inc., a Delaware corporation (the “Company”), 3,750,000 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of each share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
WARRANT TO PURCHASE COMMON STOCK RespireRx Pharmaceuticals Inc.Warrant Agreement • October 14th, 2020 • RespireRx Pharmaceuticals Inc. • Pharmaceutical preparations • New York
Contract Type FiledOctober 14th, 2020 Company Industry JurisdictionTHIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, FirstFire Global Opportunities Fund LLC or its permitted assigns (the “Holder”) is entitled, upon the terms and conditions hereof, and subject to the limitations on exercise hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. New York time on September 30, 2023 (the “Termination Date”) but not thereafter, to subscribe for and purchase from RespireRx Pharmaceuticals Inc., a Delaware corporation (the “Company”), 6,875,000 shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of each share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).